

Docket #: S18-278

Hypoxia-mediated resistance of Homologous recombination-deficient cancer cells to PARP inhibitors

Stanford researcher's invivo studies find that combining PARP inhibitors with a hypoxia activated prodrug delays tumor growth.

Applications

- Combining PARP inhibitors with Hypoxia-targeting drugs in HR deficient cancer cells

Advantages

- Combining PARP inhibitors with Tirapazamine (hypoxia-activated drug) shows significantly higher tumor killing effects when compared to each monotherapy.

Patents

- Published Application: [WO2020118251](#)

Innovators

- Amato Giaccia
- Manal Mehibel

Licensing Contact

Chu Chang

Licensing Manager, Life Sciences

[Email](#)